RxDoctor Payments Data

Marcelo Villarreal, MD

Psychiatry · Eagle Pass, TXNPI 1083704613

Payments from drug & device makers

$1,768in general payments, 2019–2025

Across 95 payments — averaging $18.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$447
  • Johnson & Johnson$297
  • AbbVie$266
  • Otsuka America Pharmaceutical, Inc.$171
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$147
  • Sanofi$91
  • plus $350 from 8 others

What the payments were for

  • Food & beverage$1,54387%
  • Education$22513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,768 in reported general payments places this provider in the 75th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$18,432
Medicare patients
49
Services billed
375

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate118$358,340
Invega TrinzaPaliperidone Palmitate33$257,673
Abilify AsimtufiiAripiprazole34$191,929
Abilify MaintenaAripiprazole37$105,235
RexultiBrexpiprazole31$48,460
SecuadoAsenapine33$47,839
UzedyRisperidone11$31,081
VraylarCariprazine Hcl17$26,254
CaplytaLumateperone Tosylate12$21,659
LybalviOlanzapine/Samidorphan Malate11$17,400
TrintellixVortioxetine Hydrobromide21$11,096
BelsomraSuvorexant21$9,398
Haloperidol Decanoate90$6,977
Paliperidone ErPaliperidone59$6,132
Aripiprazole97$5,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$297$616,013151 claims
Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Abilify Maintena, Rexulti$171$345,624102 claims
Teva Pharmaceuticals USA, Inc.Uzedy$447$31,08111 claims
AbbVieVraylar$266$26,25417 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$147$21,65912 claims
Alkermes, Inc.Lybalvi$87$17,40011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in Eagle Pass

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →